AR and posterior cortical atrophy: However, enzalutamide resistance is an urgent problem in treatment of PCa, which is induced mainly by AR point mutations, AR overexpression, and constitutively active AR splice variants (Visakorpi et al., 1995; Borgmann et al., 2018).